1. Scope

– Covered: Assessment and modification of modifiable exogenous drivers of accelerated biological ageing — tobacco/nicotine, alcohol, illicit/recreational drugs (notably opioids), and environmental exposures (ambient and household air pollution/PM2.5, heavy metals, endocrine-disrupting chemicals [EDCs], PFAS, pesticides, microplastics). Includes exposure-reduction interventions (behavioural, environmental engineering such as air filtration/water filtration) and pharmacological detoxification strategies (chelation, antioxidants) with an explicit evidence hierarchy.

– Not covered: Formal management of substance use disorder (defer to NICE CG115/NG for alcohol, and stop-smoking services), acute poisoning/overdose, occupational-disease certification, and paediatric/reproductive environmental medicine (refer to specialists).

– Positioning: Adjunctive to — never a substitute for — conventional primary/secondary care and statutory public-health measures. Ageing biomarkers (epigenetic clocks, telomere length, PhenoAge/KDM biological age, DunedinPACE) are treated throughout as surrogate endpoints, not proven hard outcomes.

2. Background and pathophysiology

Substance use and environmental exposures act less through organ-specific toxicity alone and more by driving the shared hallmarks of ageing: oxidative stress, chronic low-grade inflammation (“inflammaging”), epigenetic dysregulation, telomere attrition, mitochondrial dysfunction, and cellular senescence.[1][2][3] Oxidative stress (ROS generation) is the common molecular initiating event, propagating DNA, protein and lipid damage.[2][4]

– Air pollution (PM2.5, PM0.1, traffic-related, household combustion): the leading environmental contributor to disease burden and 4th-ranked global mortality risk factor; mediation analyses across cohorts support biological ageing as a mechanistic pathway to cardiovascular disease, neurodegeneration and CKD.[1][5]

– Tobacco smoke: genotoxic and pro-oxidant; produces reproducible DNA-methylation changes at thousands of CpG sites, some of which normalise after cessation while disease-linked sites persist for decades.[6]

– Alcohol: genotoxic via acetaldehyde, inflammation and tissue damage; relationship with ageing biomarkers is mixed/non-linear.[7][8]

– Heavy metals (lead, cadmium, arsenic, mercury): atherogenic and neurotoxic; converge on oxidative-stress and senescence pathways shared with ageing.[5][4][9]

Preclinical only (mechanistic plausibility, not clinical proof): rodent PM exposure increasing cerebral β-amyloid and hippocampal atrophy; iron-chelators (deferiprone, deferoxamine) as senomorphic/senolytic and anti-ferroptotic agents; a wide range of natural/synthetic antioxidants with combined metal-chelating and radical-scavenging activity.[5][10][4][11][12] These should not be extrapolated to human longevity practice.

3. Evidence base and grading

Available evidence spans large prospective cohorts and exposome-wide studies (air pollution, metals, EDCs), Mendelian randomisation (smoking/alcohol → telomere length), systematic reviews of epigenetic-ageing associations, and RCTs of exposure-reduction (air purifiers) and of chelation (TACT/TACT2). Outcomes studied are predominantly surrogate (biological-age clocks, telomere length, BP, inflammatory biomarkers); hard-outcome RCT data exist mainly for smoking cessation (observational), air-purifier BP effects, and chelation CV events.

Intervention / exposure	Key outcome	Evidence & certainty (GRADE-style)	Strength of recommendation	Refs
Smoking cessation	All-cause, CV, cancer, respiratory mortality	High — large cohorts; ~64% of excess CV mortality avoided within 10y, ~100% by ≥30y; consistent, direct	Strong: offer to all	[13], [14]
Alcohol reduction	All-cause mortality / ageing biomarkers	Moderate for mortality (GBD: health-loss-minimising level ≈0; J-shaped signal confounded); Low for biomarker reversal (non-linear, inconsistent)	Strong: keep ≤14 units/wk; do not initiate drinking for “benefit”	[7], [15], [16], [17]
Reduce opioid/illicit drug use	Epigenetic age acceleration	Low — cross-sectional DNAm associations (GrimAge2, DunedinPACE), residual confounding	Conditional: address as part of risk reduction	[18]
Indoor air purification (HEPA PAC)	Systolic BP, inflammatory biomarkers	Low–Very low — multiple small crossover RCTs; consistent SBP ↓~2–4 mmHg; high RoB, short duration, surrogate only	Conditional: consider in high-exposure settings	[19], [20], [21], [22]
Air purification	Hard CV events / respiratory infection	Very low / insufficient — no adequately powered long-term RCT	Only in research for hard endpoints	[19], [22]
EDTA chelation (post-MI, incl. diabetes)	MACE	Moderate overall: TACT positive (HR 0.82) but not replicated by larger, biospecimen-controlled TACT2 (HR 0.93, NS) despite 61% ↓ blood lead	Recommend against for CV prevention/longevity	[9], [23], [24]
Antioxidant supplements for metal toxicity	Clinical outcomes	Very low — human data insufficient; possible pro-oxidant harm	Only in research	[11], [12]
Exposure-reduction (diet, water/air filtration, avoidance)	Biological-age clocks	Low — cohort/EWAS associations; clocks are investigational	Conditional: reasonable, low-harm	[2], [6], [20], [25]

Overarching caveats: (i) epigenetic-clock findings for air pollution are inconclusive at meta-analytic level despite biological plausibility, whereas composite biological-age indices (KDM, PhenoAge) and frailty show the most robust associations; (ii) publication bias and small-study effects are likely in air-purifier and antioxidant literature; (iii) surrogate improvement has[1][25] not been shown to translate into hard-outcome benefit for these interventions.

4. Patient selection and indications

– Who may benefit (inclusion):

– Any current smoker/vaper or hazardous drinker (>14 units/week) — highest-yield, guideline-based targets.[13][14][17]

– Middle-aged adults with high cardiometabolic risk and identifiable high exposure (traffic-related/household air pollution, occupational metals, private-well or soft-water supplies).[5][20]

– People with disproportionate exposure: living/working near manufacturing, waste-processing, high-traffic corridors, wildfire-affected regions; firefighters, food/hospitality workers (PFAS).[26][20]

– Older adults with frailty in high-PM2.5 environments, where composite biological-age and frailty associations are strongest.[1]

– Exclusion / specialist-input groups:

– Do not offer EDTA chelation for cardiovascular/longevity indications — reserve for genuine clinical heavy-metal poisoning under toxicology.[9]

– Renal impairment, pregnancy/breastfeeding, and frailty: avoid pharmacological “detox” without specialist input.

– Suspected significant toxic exposure with diagnostic uncertainty → refer to occupational/environmental medicine or a toxicology service.[26][27]

– Regulatory/ethical status:

– Smoking cessation and alcohol reduction: on-label / guideline-based.

– Air/water filtration and exposure avoidance: non-medical, low-harm; frame as risk reduction with realistic (surrogate-level) expectations.

– Chelation for longevity: off-label and recommended against; antioxidant “detox” protocols and metal-provoked urine testing: experimental / not validated, offer only within research frameworks with informed consent.

5. Assessment and baseline work-up

– History: structured exposure history — occupation, home (heating/cooking fuel, damp, renovation, water source), hobbies (soldering, firearms, ceramics, fishing), residential proximity to traffic/industry, diet (ground spices, large predatory fish), consumer products/PFAS. Full substance history: tobacco/nicotine (pack-years), alcohol (units/week; use AUDIT-C), recreational/illicit and non-prescription opioid use.[18][26][27]

– Examination: cardiometabolic and respiratory focus; frailty assessment in older adults.

– Baseline investigations:

– Standard: BP, HbA1c/lipids, U&E/eGFR, LFTs, FBC.

– Targeted biomonitoring only when exposure history warrants — blood lead and mercury are the established clinical measurements; most other chemicals lack validated clinical assays and testing is largely research-only. NASEM suggests PFAS testing for those with likely elevated exposure.[26]

– Do not use unvalidated “provoked” (post-chelation) urine metal testing to justify treatment — not evidence-based.

– Optional ageing biomarkers (investigational, for tracking/engagement, not diagnosis): composite biological-age indices (PhenoAge, KDM) and DunedinPACE are the most robust for exposure associations; document alongside — never in place of — clinical measures.[1][18][25]

– Risk stratification: stratify by exposure intensity × host vulnerability (age, cardiometabolic/respiratory disease, frailty, APOE ε4 for air-pollution neuro-risk). Reserve pharmacological interventions for confirmed toxic exposure only.[5]

6. Dosing regimens and practical implementation

Robust human data (offer):

– Smoking cessation — behavioural support plus pharmacotherapy per NICE/NHS stop-smoking pathway; benefit accrues at any age, greatest if quit by 40.[13][14]

– Alcohol — keep ≤14 units/week spread over ≥3 days with drink-free days (UK CMO); no lower threshold is “cardioprotective” enough to recommend initiation.[17][15]

Reasonable, low-harm exposure reduction (consider):

– Indoor air: HEPA portable air cleaner sized to room, run continuously; reduces indoor PM2.5 by ~50–70% and lowers SBP ~2–4 mmHg in trials. Avoid outdoor exertion during poor air-quality episodes; use in-vehicle/indoor air-conditioning on recirculation; clean cooking fuels.[19][20][28]

– Water/diet: point-of-use water filtration where metal/PFAS contamination is plausible; minimise contaminated ground spices, limit high-mercury fish.[20]

– PFAS body burden: blood/plasma donation and cholestyramine can lower PFAS stores, but cardiovascular/longevity benefit is unproven — present as mechanistic only.[20]

Extrapolated/early-phase — use caution or research only:

– EDTA chelation: the TACT regimen (40 weekly then spaced infusions of disodium EDTA + ascorbate/B-vitamins) is described for completeness but is recommended against for CV/longevity use after TACT2.[9][24]

– Antioxidant “detox” regimens (NAC, α-lipoic acid, quercetin, etc.): insufficient human evidence; possible pro-oxidant harm at high doses — do not recommend outside trials.[11][12]

7. Monitoring, safety and follow-up

– Monitoring plan: for cessation/reduction, track abstinence, BP, weight/metabolic parameters. For confirmed metal exposure under specialist care, monitor the relevant blood metal level and renal function. Optional periodic re-measurement of a composite biological-age index for engagement, interpreted cautiously.

– Timepoints: short-term (4–12 weeks) for adherence and BP; medium-term (3–6 months) for metabolic/biomarker trends; long-term (annual) for cardiometabolic risk. Biological-age clocks respond slowly and are not validated for short-interval monitoring.[29][25]

– Adverse effects:

– Behavioural interventions: minimal; manage nicotine withdrawal and alcohol-withdrawal risk (screen dependent drinkers before advising abrupt cessation — refer per NICE if dependence).

– Air purifiers: negligible harm; cost and maintenance are the main issues.

– EDTA chelation: ~15% discontinued infusions for adverse events in TACT; risks include hypocalcaemia, renal injury, and rare deaths — a key reason to avoid non-indicated use.[24][9]

– High-dose antioxidants: potential pro-oxidant effects and interference with therapy.[12]

– Interactions/comorbidity: EDTA depletes divalent cations (calcium, zinc); caution with renal impairment and diuretics. Cholestyramine (if used for PFAS) binds many drugs and fat-soluble vitamins — separate dosing.

– Special populations: avoid chelation and unvalidated detox in pregnancy, breastfeeding, and renal/hepatic impairment; in frailty and extremes of age prioritise low-harm environmental measures over pharmacology; smoking cessation and alcohol reduction remain beneficial at all ages.[14]

8. Contraindications and cautions

– Absolute: EDTA chelation in renal failure or without a genuine poisoning indication; unsupervised abrupt alcohol cessation in physically dependent patients (delirium tremens risk).

– Relative / specialist advice: confirmed heavy-metal poisoning (toxicology-led chelation only); PFAS-lowering strategies where drug interactions or nutritional deficiency are a concern; high-dose antioxidant regimens with concurrent oncological or cardiovascular therapy.

– Harm likely to outweigh benefit (current evidence): EDTA chelation for CV prevention/longevity; provoked-urine metal testing to justify treatment; antioxidant “detox” protocols marketed for anti-ageing.[9][12]

9. Practical management scenarios

Scenario A — Middle-aged adult, multiple cardiometabolic risk factors, urban/high-traffic exposure. Recommendation: Offer behavioural exposure reduction (Strong for smoking/alcohol; Conditional for air filtration).

– Assessment: exposure + substance history, AUDIT-C, pack-years, BP/metabolic panel; blood lead/mercury only if history warrants.

– Shared decision-making: frame smoking cessation and alcohol ≤14 units as highest-yield, guideline-based; frame air filtration as low-harm with surrogate-level (BP/inflammation) benefit.

– Initiation: stop-smoking pathway + pharmacotherapy; alcohol brief intervention; HEPA PAC at home; air-quality-aware activity.

– Monitoring: BP and adherence at 4–12 weeks; metabolic risk annually.

– Escalate/stop: refer for dependence; refer to environmental/occupational medicine if occupational exposure suspected.[26][13][17][19]

Scenario B — Older, frail patient with multimorbidity in a high-PM2.5 area. Recommendation: Consider low-harm environmental measures; avoid pharmacological detox/chelation.

– Assessment: frailty and polypharmacy review; realistic goal-setting.

– Shared decision-making: prioritise interventions with minimal burden (home HEPA filtration, avoiding outdoor exertion on poor-air days) given robust exposure–frailty/biological-age associations.[1]

– Initiation: environmental engineering only; continue guideline-based cardiometabolic care.

– Monitoring: BP, function, tolerability.

– Escalate/stop: stop any measure that increases burden without benefit; refer if new toxic exposure suspected.

Scenario C — Patient under specialist care (e.g. post-MI, diabetes) requesting “detox”/chelation as an adjunct. Recommendation: Avoid/recommend against chelation and antioxidant detox for CV/longevity; offer guideline-based risk reduction.

– Assessment: confirm optimisation of secondary prevention; take exposure history.

– Shared decision-making: explain that TACT2 showed no MACE reduction despite a 61% fall in blood lead, so chelation is not justified for CV benefit.[9]

The following JAMA visual abstract summarises the definitive negative TACT2 result underpinning this recommendation:

– Initiation: redirect to smoking cessation, alcohol reduction, exposure avoidance and home air filtration; coordinate with the treating specialist.

– Monitoring/escalate: standard secondary-prevention follow-up; refer to toxicology only for genuine poisoning.

10. Research gaps and future directions

– Hard-outcome evidence: no adequately powered, long-term RCT shows that exposure-reduction (air/water filtration, PFAS lowering) reduces mortality or major clinical events — current trials are small, short, high-RoB, and surrogate-limited. Restrict hard-endpoint claims to research/registries.[19][21][22]

– Biomarker validity: epigenetic clocks respond inconsistently to air pollution and are not validated as monitoring tools; composite biological-age and frailty indices need prospective intervention data linking change to clinical benefit.[1][29][25]

– Priority questions: optimal filtration “dose”/duration for durable cardiovascular benefit; whether lowering PFAS/metal body burden alters clinical outcomes; whether reducing opioid/illicit drug exposure reverses biological-age acceleration prospectively; safe, effective antioxidant strategies (if any) versus pro-oxidant harm.[18][20][12]

– Populations: under-representation of household air pollution, low-income and non-White populations, and longitudinal multi-omics designs.[1]

– Practice stance: the highest-certainty, guideline-backed longevity interventions here remain smoking cessation and alcohol moderation; environmental measures are low-harm and reasonable; chelation and antioxidant “detox” for longevity should remain within trials only.




Figure 4 Environmental architectures of age-related biological mechanisms and diseases in the UKB. Argentieri MA, Amin N, Nevado-Holgado AJ, et al. Integrating the Environmental and Genetic Architectures of Aging and Mortality. Nature Medicine. 2025;31(3):1016-1025. doi:10.1038/s41591-024-03483-9.

 

Figure 3 Forest plot of exposome associations with all-cause mortality (n = 436,891) in multivariable models for each individual cluster of correlated exposures. Argentieri MA, Amin N, Nevado-Holgado AJ, et al. Integrating the Environmental and Genetic Architectures of Aging and Mortality. Nature Medicine. 2025;31(3):1016-1025. doi:10.1038/s41591-024-03483-9.

 

Figure 2 Kaplan-Meier Estimates of the Primary Composite End Point, EDTA Chelation Therapy vs Placebo Lamas GA, Goertz C, Boineau R, et al. Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction: The TACT Randomized Trial. Jama. 2013;309(12):1241-50. doi:10.1001/jama.2013.2107.

 

Figure 2 Cumulative Incidence of Time to First Event Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial. Jama. 2024;332(10):794-803. doi:10.1001/jama.2024.11463.

 

Central Illustration Central Illustration. Chen R, Zhao A, Chen H, et al. Cardiopulmonary Benefits of Reducing Indoor Particles of Outdoor Origin: A Randomized, Double-Blind Crossover Trial of Air Purifiers. Journal of the American College of Cardiology. 2015;65(21):2279-87. doi:10.1016/j.jacc.2015.03.553.

References

1. Aging in the Air We Breathe: Mechanisms and Consequences of Air Pollution Exposure for Biological Aging. Poursafa P, Jylhävä J. Ageing Research Reviews. 2026;:103297. doi:10.1016/j.arr.2026.103297.
2. Environmental Health Is Overlooked in Longevity Research. Mesnage R. Antioxidants (Basel, Switzerland). 2025;14(4):421. doi:10.3390/antiox14040421.
3. Exposome and Unhealthy Aging: Environmental Drivers From Air Pollution to Occupational Exposures. Pandics T, Major D, Fazekas-Pongor V, et al. GeroScience. 2023;45(6):3381-3408. doi:10.1007/s11357-023-00913-3.
4. Heavy Metal Exposure: Molecular Pathways, Clinical Implications, and Protective Strategies. Koyama H, Kamogashira T, Yamasoba T. Antioxidants (Basel, Switzerland). 2024;13(1):76. doi:10.3390/antiox13010076.
5. To promote healthy aging, focus on the environment. Belsky DW, Baccarelli AA. Nature Aging. 2023;3(11):1334-1344. doi:10.1038/s43587-023-00518-7.
6. Molecular mechanisms of environmental exposures and human diseases. Wu H, Eckhardt CM, Baccarelli AA. Nature Reviews. Genetics. 2023;24(5):332-344. doi:10.1038/s41576-022-00569-3.
7. Methylomic Aging as a Window Onto the Influence of Lifestyle: Tobacco and Alcohol Use Alter the Rate of Biological Aging. Beach SR, Dogan MV, Lei MK, et al. Journal of the American Geriatrics Society. 2015;63(12):2519-2525. doi:10.1111/jgs.13830.
8. Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care. Carroll JE, Bower JE, Ganz PA. Nature Reviews. Clinical Oncology. 2022;19(3):173-187. doi:10.1038/s41571-021-00580-3.
9. Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes. Lamas GA, Anstrom KJ, Navas-Acien A, et al. JAMA. 2024;332(10):794-803. doi:10.1001/jama.2024.11463.
10. Targeting Aging and Diseases Associated With Ferroptosis and Senescence Through Modulation of Iron, Oxidative Stress and Lipid Peroxidation. Kourti M, Kontoghiorghes GJ. Antioxidants (Basel, Switzerland). 2025;15(1):15. doi:10.3390/antiox15010015.
11. Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity. Flora SJ, Shrivastava R, Mittal M. Current Medicinal Chemistry. 2013;20(36):4540-74. doi:10.2174/09298673113209990146.
12. Structural, Chemical and Biological Aspects of Antioxidants for Strategies Against Metal and Metalloid Exposure. Flora SJ. Oxidative Medicine and Cellular Longevity. 2009 Sep-Oct;2(4):191-206. doi:10.4161/oxim.2.4.9112.
13. Association of Smoking Cessation and Cardiovascular, Cancer, and Respiratory Mortality. Thomson B, Islami F. JAMA Internal Medicine. 2024;184(1):110-112. doi:10.1001/jamainternmed.2023.6419.
14. Reprint Of: Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. Kalkhoran S, Benowitz NL, Rigotti NA. Journal of the American College of Cardiology. 2018;72(23 Pt B):2964-2979. doi:10.1016/j.jacc.2018.10.020.
15. Population-Level Risks of Alcohol Consumption by Amount, Geography, Age, Sex, and Year: A Systematic Analysis for the Global Burden of Disease Study 2020. GBD 2020 Alcohol Collaborators. Lancet (London, England). 2022;400(10347):185-235. doi:10.1016/S0140-6736(22)00847-9.
16. The Effects of Modest Drinking on Life Expectancy and Mortality Risks: A Population-Based Cohort Study. Liu YT, Lee JH, Tsai MK, Wei JC, Wen CP. Scientific Reports. 2022;12(1):7476. doi:10.1038/s41598-022-11427-x.
17. New UK alcohol guidelines and Dry January: enough to give up boozing?. Cabezas J, Bataller R. Nature Reviews. Gastroenterology & Hepatology. 2016;13(4):191-2. doi:10.1038/nrgastro.2016.39.
18. Substance Use and Epigenetic Age Acceleration: Associations With Alcohol, Tobacco, Illicit Drugs, and SUD Severity. Fekete M, Mitchell C, Gibb J, Perry BL. Drug and Alcohol Dependence. 2026;287:113269. doi:10.1016/j.drugalcdep.2026.113269.
19. Air pollution interventions for health. Ji JS, Dominici F, Gouveia N, Kelly FJ, Neira M. Nature Medicine. 2025;31(9):2888-2900. doi:10.1038/s41591-025-03929-8.
20. Personal Strategies to Reduce the Cardiovascular Impacts of Environmental Exposures. Bonanni LJ, Newman JD. Circulation Research. 2024;134(9):1197-1217. doi:10.1161/CIRCRESAHA.123.323624.
21. The Effect of Using Personal-Level Indoor Air Cleaners and Respirators on Biomarkers of Cardiorespiratory Health: A Systematic Review. Liu S, Wu R, Zhu Y, et al. Environment International. 2022;158:106981. doi:10.1016/j.envint.2021.106981.
22. Effectiveness of indoor air purification intervention in improving cardiovascular health: A systematic review and meta-analysis of randomized controlled trials. Xia X, Chan KH, Lam KBH, et al. The Science of the Total Environment. 2021;789:147882. doi:10.1016/j.scitotenv.2021.147882.
23. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Virani SS, Newby LK, Arnold SV, et al. Journal of the American College of Cardiology. 2023;82(9):833-955. doi:10.1016/j.jacc.2023.04.003.
24. Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction: The TACT Randomized Trial. Lamas GA, Goertz C, Boineau R, et al. JAMA. 2013;309(12):1241-50. doi:10.1001/jama.2013.2107.
25. Chemical and Climatic Environmental Exposures and Epigenetic Aging: A Systematic Review. Fadadu RP, Bozack AK, Cardenas A. Environmental Research. 2025;274:121347. doi:10.1016/j.envres.2025.121347.
26. Health Effects of Fossil Fuel–Derived Endocrine Disruptors. Woodruff TJ. The New England Journal of Medicine. 2024;390(10):922-933. doi:10.1056/NEJMra2300476.
27. Addressing Environmental Health: Clinician Training and Practice of Environmental Medicine-Acoem Guidance Statement. Berenji M, Baker B, Saberi P, et al. Journal of Occupational and Environmental Medicine. 2024;66(12):e668-e673. doi:10.1097/JOM.0000000000003246.
28. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Nature Reviews. Cardiology. 2020;17(10):656-672. doi:10.1038/s41569-020-0371-2.
29. Non-pharmaceutical interventions and epigenetic aging in adults: Protocol for a scoping review. Liebich A, Zheng S, Schachner T, et al. PloS One. 2024;19(8):e0301763. doi:10.1371/journal.pone.0301763.
30. Integrating the environmental and genetic architectures of aging and mortality. Argentieri MA, Amin N, Nevado-Holgado AJ, et al. Nature Medicine. 2025;31(3):1016-1025. doi:10.1038/s41591-024-03483-9.
31. Cardiopulmonary Benefits of Reducing Indoor Particles of Outdoor Origin: A Randomized, Double-Blind Crossover Trial of Air Purifiers. Chen R, Zhao A, Chen H, et al. Journal of the American College of Cardiology. 2015;65(21):2279-87. doi:10.1016/j.jacc.2015.03.553.